Literature DB >> 31770100

Elevated levels of arachidonic acid metabolites in follicular fluid of PCOS patients.

Shengxian Li1, Jia Qi2,3, Yongzhen Tao4, Qinling Zhu2,3, Rong Huang1, Yu Liao1, Jiang Yue1, Wei Liu1, Hanting Zhao2,3, Huiyong Yin4,5,6, Yun Sun2,3.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women usually accompanied by lipid metabolic disorders. However, it remains unknown whether arachidonic acid (AA) and its metabolites in follicular fluid (FF) were altered in PCOS patients. This study was intended to measure the levels of AA and its metabolites in the FF of non-obese PCOS patients that underwent in vitro fertilization (IVF) and to explore the possible causes of the alterations. Thirty-nine non-obese women with PCOS and 30 non-obese women without PCOS were enrolled. AA and its metabolites were measured by liquid chromatography-mass spectrometry. The levels of AA metabolites generated via cyclooxygenase-2 (COX-2) pathway and cytochrome P450 epoxygenase pathway but not lipoxygenase (LOX) pathway were significantly higher in the FF of PCOS patients. The metabolites generated via COX-2 pathway were significantly correlated with levels of testosterone and fasting insulin in serum. The in vitro study further demonstrated that insulin but not testosterone could promote the IL-1β and hCG-induced COX-2 expression and prostaglandin E2 (PGE2) secretion in primary human granulosa cells. In conclusion, there was an elevation in AA metabolites in FF of PCOS patients. Insulin played a pivotal role in the increased AA metabolites generated via COX-2, which could be interpreted as another novel molecular pathophysiological mechanism of PCOS.

Entities:  

Year:  2020        PMID: 31770100     DOI: 10.1530/REP-19-0136

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  7 in total

Review 1.  Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome.

Authors:  Ana Teresa Brinca; Ana Cristina Ramalhinho; Ângela Sousa; António Hélio Oliani; Luiza Breitenfeld; Luís A Passarinha; Eugenia Gallardo
Journal:  Biomedicines       Date:  2022-05-27

Review 2.  Inflammation and reproductive function in women with polycystic ovary syndrome†.

Authors:  Leandro M Velez; Marcus Seldin; Alicia B Motta
Journal:  Biol Reprod       Date:  2021-06-04       Impact factor: 4.285

3.  Correlation between steroid levels in follicular fluid and hormone synthesis related substances in its exosomes and embryo quality in patients with polycystic ovary syndrome.

Authors:  Li Yu; Miao Liu; Zhenxin Wang; Te Liu; Suying Liu; Beili Wang; Baishen Pan; Xi Dong; Wei Guo
Journal:  Reprod Biol Endocrinol       Date:  2021-05-17       Impact factor: 5.211

4.  Genetically Predicted Cigarette Smoking in Relation to Risk of Polycystic Ovary Syndrome.

Authors:  Yingli Tao; Bin Liu; Ying Chen; Yiduoduo Hu; Rui Zhu; Ding Ye; Yingying Mao; Xiaohui Sun
Journal:  Clin Epidemiol       Date:  2021-07-02       Impact factor: 4.790

5.  miR‑132 is upregulated in polycystic ovarian syndrome and inhibits granulosa cells viability by targeting Foxa1.

Authors:  Xiangrong Cui; Xuan Jing; Junfen Liu; Xingyu Bi; Xueqing Wu
Journal:  Mol Med Rep       Date:  2020-10-14       Impact factor: 2.952

6.  Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome.

Authors:  Ling Zhou; Zhexin Ni; Jin Yu; Wen Cheng; Zailong Cai; Chaoqin Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-08       Impact factor: 5.555

7.  UHPLC-MS-MS analysis of oxylipins metabolomics components of follicular fluid in infertile individuals with diminished ovarian reserve.

Authors:  Chengcheng Liang; Xiaole Zhang; Cong Qi; Hui Hu; Qinhua Zhang; Xiuxian Zhu; Yonglun Fu
Journal:  Reprod Biol Endocrinol       Date:  2021-09-14       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.